JP Morgan Maintains Overweight on TransMedics Gr, Lowers Price Target to $116
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Allen Gong maintains an Overweight rating on TransMedics Group (NASDAQ:TMDX) but lowers the price target from $173 to $116.
October 29, 2024 | 3:11 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
JP Morgan has maintained an Overweight rating on TransMedics Group but has significantly lowered the price target from $173 to $116, indicating a more cautious outlook.
The reduction in the price target from $173 to $116 by JP Morgan suggests a more cautious outlook on TransMedics Group's future performance, which could lead to a negative short-term impact on the stock price despite the maintained Overweight rating.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100